---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-003042"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:42:19.132759+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss

## Summary
- Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).
- 28% of subjects on imdusiran + 24 weeks of IFN achieved HBsAg below lower limit of quantification with anti-HBs.
- Imdusiran followed by VTP-300 maintained lower HBsAg levels; more subjects qualified to stop NA therapy and remain off therapy.
- Additional on-treatment, follow-up, and NA discontinuation data to be presented at the meeting.

## SEC filing metadata
- accession: 0001171843-24-003042
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/0001171843-24-003042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324003042/f8k_052224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-003042
- JSON: https://secwatch.observer/filing/0001171843-24-003042.json
- Plain text: https://secwatch.observer/filing/0001171843-24-003042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.